Natera, Inc.

Natera, Inc. is a diagnostics company that develops and commercializes molecular testing services globally. Its portfolio includes Signatera, a personalized ctDNA blood test for minimal residual disease (MRD) assessment, early recurrence monitoring, and treatment response evaluation in cancer patients. Other key offerings are Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue-based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. In reproductive health, Natera provides Panorama (non-invasive prenatal test), Horizon (carrier screening), and Vistara (single-gene NIPT). It also offers Anora for miscarriage tissue analysis, Prospera for transplant rejection assessment, Renasight for kidney gene panel testing, and Constellation software for cloud-based distribution. Additionally, Natera provides phlebotomy and EMR integration services.

Natera, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol NTRA. Its shares are traded in US dollars (USD). The company is headquartered in the United States and operates primarily in the US market, though its services are available globally.

Natera operates in the Healthcare sector, specifically within the Diagnostics & Research industry. This means the company focuses on developing and providing diagnostic testing services and research tools, primarily for oncology, reproductive health, and organ transplantation. Its molecular tests help in early detection, monitoring, and personalized treatment decisions.

Natera's main products include a range of molecular diagnostic tests. In oncology, its flagship test is Signatera, a personalized ctDNA blood test for MRD assessment and recurrence monitoring. Latitude is a blood-based MRD test for colorectal cancer, and Altera is a tissue-based genomic profiling test. For reproductive health, Panorama is a non-invasive prenatal test, Horizon screens for carrier status, and Vistara screens for single-gene conditions. Anora analyzes miscarriage tissue. For transplant patients, Prospera assesses active rejection. Renasight is a kidney gene panel test. The company also offers Constellation software for cloud-based data distribution, phlebotomy services, and EMR integration services. These products serve independent labs, reference labs, medical centers, physician practices, research labs, and pharmaceutical companies.

Natera generates revenue primarily by selling its molecular diagnostic tests and related services to a variety of customers. Its clients include independent laboratories, national and regional reference laboratories, medical centers, physician practices, research laboratories, and pharmaceutical companies. The company uses a direct sales force to market its tests. In addition to test sales, Natera offers Constellation software as a cloud-based distribution model, phlebotomy services, and electronic medical record (EMR) integration services, which likely contribute to its revenue streams. The tests are used for screening, monitoring, and treatment guidance in oncology, reproductive health, and transplantation.